Emergent Biosolutions Inc.

The stock has a good momentum. Emergent Biosolutions Inc. has good value characteristics. Emergent Biosolutions Inc. has good growth characteristics. Emergent Biosolutions Inc. is not very popular among insiders. Emergent Biosolutions Inc. is a mediocre stock to choose.
Log in to see more information.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical...
EBS Fundamental Data by TradingView

News

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola
Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola

Globe Newswire GAITHERSBURG, Md., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a contract modification executing an option period by the Biomedical...\n more…

OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing
OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing

Globe Newswire New York, New York, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oak Hill Advisors ( OHA ) served as Administrative Agent and sole lender of a $250 million term loan facility supporting Emergent BioSolutions...\n more…

Emergent BioSolutions' smallpox vaccine approved as treatment for mpox
Emergent BioSolutions' smallpox vaccine approved as treatment for mpox

BizJournals.com - Nat'l Business News Emergent BioSolutions won a key approval from the FDA that will allow its smallpox vaccine to be used in the global fight to contain mpox.\n more…

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile
Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

Globe Newswire New favorable terms position Emergent for sustainable, long-term growth, as part of its multi-year plan to stabilize, turnaround and transform the companyGAITHERSBURG, Md., Sept. 03, 2024 (GLOBE...\n more…

This vaccine stock surged after the FDA cleared it for mpox
This vaccine stock surged after the FDA cleared it for mpox

Quartz Emergent BioSolutions (EBS) surged early Friday morning, following news that one of its vaccines got approval from the U.S. Food and Drug Administration (FDA) to prevent mpox (formerly known as...\n more…

Emergent BioSolutions rises 11.6%
Emergent BioSolutions rises 11.6%

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…